Document is current
Any future updates will be listed below
-
Authors
Zhao, Yifan https://orcid.org/0000-0003-4829-1428
Luquette, Lovelace J. https://orcid.org/0000-0001-6968-9043
Veit, Alexander D.
Wang, Xiaochen
Xi, Ruibin https://orcid.org/0000-0001-7545-7361
Viswanadham, Vinayak V. https://orcid.org/0000-0002-0236-6490
Zhang, Yuwei https://orcid.org/0000-0003-4917-8056
Shao, Diane D.
Walsh, Christopher A. https://orcid.org/0000-0002-0156-2238
Yang, Hong Wei
Johnson, Mark D. https://orcid.org/0000-0002-4010-2605
Park, Peter J. https://orcid.org/0000-0001-9378-960X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA269805, R01HG012573, F31CA264958)
- License Information
-
More Information
Article History
Received: 20 March 2024
Accepted: 24 May 2025
First Online: 1 July 2025
Competing interests
: P.J.P. is a member of the scientific advisory board (SAB) for Bioskryb Genomics, Inc. C.A.W. is a member of the SAB of Bioskryb Genomics, Inc. (cash, equity), Mosaica Therapeutics (cash, equity), and an advisor to Maze Therapeutics (equity). The remaining authors declare no competing interests.
